Evaluation of radiologic evidence of metabolic bone disease in very low birth weight infants at fourth week of life

Creative Commons License

Kavurt S., DEMİREL N., Yücel H., Unal S., Yıldız Y. T., BAŞ A. Y.

Journal of Perinatology, vol.41, no.11, pp.2668-2673, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 41 Issue: 11
  • Publication Date: 2021
  • Doi Number: 10.1038/s41372-021-01065-y
  • Journal Name: Journal of Perinatology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.2668-2673
  • Ankara Yıldırım Beyazıt University Affiliated: Yes

Abstract

© 2021, The Author(s), under exclusive licence to Springer Nature America, Inc.Aim: The aim of this study is to determine the incidence of metabolic bone disease (MBD) and assess the risk factors for development radiologic evidence of MBD. Methods: Preterm infants with gestational age ≤32 weeks and birth weight ≤1500 g were included in this prospective study. Metabolic bone disease was defined as hypophosphatemia (phosphorus levels <4 mg/dl), ALP levels >450 U/L, or radiologic findings of MBD at four weeks of age. Results: The study included 254 infants (gestational age: 29 (27–30) weeks, birth weight: 1130 g (960–1300)). Metabolic bone disease was diagnosed in 96 patients (37%); 48 infants had only radiologic evidence of MBD, 24 infants had only biochemical diagnosis of MBD, and 24 infants had both radiologic evidence of MBD and biochemical diagnosis of MBD. Conclusions: Our results showed that radiologic evidence of MBD existed in some infants with normal biochemical results. That finding may guide further development of screening programs for MBD.